- To provide an update on key diagnostic, clinical, molecular, prognostic and predictive characteristics in patients with newly diagnosed and recurrent glioblastoma
- To describe best practices and current treatment recommendations
- To provide an update on recent clinical trials and ongoing research seeking to improve treatment outcomes
After two years E-Learning modules are no longer considered current. There is therefore no CME test associated with this E-Learning module.
|Title||Duration||Content||CME Points||CME Test|
|Multidisciplinary Treatment for Glioblastoma||20 min.||25 slides||-||-|
Glioblastoma is the most common primary brain tumour in adult patients. It is a cancer type characterised with a high morbidity and mortality, with a median overall survival of 14 to 17 months. This E-learning module is part of ESMO effort to provide an update on standard treatment recommendations and raise interest among a new generation of oncologists towards a type of disease in which research is a key factor towards improved outcomes.
Most patients develop de novo tumours with a short clinical history of days to a few months (primary glioblastoma) and less than 10% of tumours develop from lower grade gliomas (secondary glioblastomas), typically with a clinical history of years. The clinical presentation is highly variable and it depends on tumour localisation and size.
Standard first-line therapy consists of maximal safe resection and combined radiochemotherapy with temozolomide. Currently there is no accepted treatment standard for recurrent glioblastoma. Supportive treatment with anti-oedema and anticonvulsive therapy is of particular importance in most patients. Ongoing trials evaluate novel strategies for newly diagnosed glioblastoma and patients with recurrent glioblastoma.
In this E-learning module, the author covers in a very educational manner:
- epidemiology of glioblastoma,
- relative frequencies of gliomas,
- risk factors,
- clinical presentation,
- neuroimaging features,
- histopathology features,
- molecular pathology,
- prognostic factors,
- standard treatment strategies in newly diagnosed and patients with recurrent glioblastoma,
- current therapy schedule and key recommendations based on randomised phase III trials,
- treatment specificities in elderly patients,
- standards in anti-oedema and anticonvulsive therapies, as well as a summary on currently ongoing research strategies
This E-Learning module was published in 2015 and expired in 2017.
The author has reported to have received grants from Roche, GSK, Boehringer-Ingelheim, MSD and honoraria from GSK, Roche and BMS